OPC Pharmaceutical JSC

OPC maintains a strong liquidity position, with cash and equivalents amounting to VND 180.8 billion, representing 13.2% of total assets. The company's current ratio of 2.72 indicates a solid ability to meet short-term obligations, and its debt-to-equity ratio of 0.0 suggests no long-term debt burden. This liquidity profile is well above the typical pharmaceutical industry median, where debt leverage is often higher. Profitability metrics show OPC is performing well relative to industry norms. Return on equity (ROE) of 12.73% and return on assets (ROA) of 8.45% are both above the median for the pharmaceutical sector, indicating efficient use of equity and assets to generate returns. Gross profit of VND 464.9 billion and operating income of VND 148.2 billion further support strong operational performance. Geographically, OPC is concentrated in Vietnam, with no disclosed international revenue segments. Its business is entirely domestic, and it operates across multiple product lines, including pharmaceuticals, functional food, and bottled water. Revenue concentration in a single country exposes the company to local economic and regulatory risks, but it also allows for focused operational control. Looking ahead, OPC is projected to grow revenue by 12.5% in the current fiscal year and 8.2% in the next, based on historical trends and disclosed capital expenditure plans. The company's free cash flow of VND 119.9 billion provides flexibility for reinvestment or shareholder returns, though no specific guidance on dividends or buybacks is currently available. Risk factors for OPC are minimal in the short term. The company has no long-term debt, and no dilution flags were detected in recent filings. However, the absence of debt could also indicate limited financial leverage, which may constrain growth in capital-intensive projects. The risk assessment composite score is low, with no immediate liquidity or dilution concerns. Recent events include the dissolution of OPC EXIM Real Estate Joint Stock Company in 2014, which suggests a strategic refocusing on core pharmaceutical and consumer goods operations. No recent filings or transcripts indicate material changes in business strategy or financial outlook.